| Literature DB >> 27042312 |
Runar Unhjem1, Grete Flemmen2, Jan Hoff3, Eivind Wang4.
Abstract
BACKGROUND: Patients with substance use disorder (SUD) suffer from multiple health and psychosocial problems. Because poor physical capacities following an inactive lifestyle may indeed contribute to these problems, physical training is often suggested as an attractive supplement to conventional SUD treatment. Strength training is shown to increase muscle strength and effectively improve health and longevity. Therefore we investigated the feasibility and effect of a maximal strength training intervention for SUD patients in clinical treatment.Entities:
Keywords: Mental health; Muscle strength; One repetition maximum; Physical health; Rate of force development; V-wave
Year: 2016 PMID: 27042312 PMCID: PMC4818502 DOI: 10.1186/s13102-016-0032-2
Source DB: PubMed Journal: BMC Sports Sci Med Rehabil ISSN: 2052-1847
Fig. 1CONSORT flow diagram of study design
Patient characteristics and medical use
| TG ( | CG ( | Combined ( | |
|---|---|---|---|
| Men/Women (n) | 6/3 | 7/0 | 13/3 |
| Age (yr) | 33 ± 9 | 29 ± 5 | 32 ± 8 |
| Weight (kg) | 80.2 ± 18.2 | 81.8 ± 9.6 | 80.9 ± 14.3 |
| Height (cm) | 173 ± 10 | 181 ± 5 | 177 ± 9 |
| First time drug use (age) | 14 ± 2 | 15 ± 2 | 14 ± 2 |
| Duration of abuse (yr) | 13 ± 10 | 11 ± 4 | 12 ± 8 |
| Current Smoker | 7 | 6 | 13 |
| Primary drug: | |||
| Amphetamine | 9 | 7 | 16 |
| Secondary drug: | |||
| Alcohol | 4 | 1 | 5 |
| Cocaine | 1 | 1 | |
| Cannabis | 5 | 5 | 10 |
| Symptoms for medicine prescription: | |||
| ADHD | 1 | 1 | 2 |
| Allergies | 3 | 4 | 7 |
| Anxiety | 3 | 3 | |
| Arthiritis | 2 | 2 | |
| Asthma/COPD | 3 | 1 | 4 |
| Depression | 3 | 1 | 4 |
| Epilepsy | 1 | 1 | |
| Hypertension | 5 | 5 | |
| Schizofenia/Bipolar | 4 | 1 | 5 |
| Migrene | 3 | 3 | |
| Substitutional treatment | 1 | 1 | |
| Other | 5 | 1 | 6 |
Data are presented as mean ± SD, TG; training group, CG; control group. Type of medication is reported on indication of symptoms according to common directory. The prescribed medicine in substitutional treatment is subuxone. Others: atherothrombosis, diabetes, infections
Fig. 2Hack squat one repetition maximum (1RM) for (a) the training group and (b) the control group from pre- to posttest. * p < 0.01, difference within group from pre- to posttest. # p < 0.01, difference between groups from pre- to posttest
Fig. 3Hack squat rate of force development for (a) the training group and (b) the control group from pre- to posttest. * p < 0.01, difference within group from pre- to posttest. # p < 0.01, difference between groups from pre- to posttest
Fig. 4Data are presented as mean ± SE. Maximal V-wave/maximal M-wave (V/M-ratio) for the training group at pre- and posttest. * p < 0.01, difference within group from pre- to posttest. # p < 0.01, different from the control group from pre- to posttest
Psychological measurements, changes from pre- to posttest (scores from insomnia severity index and hospital anxiety and depression scale questionnaires)
| TG ( | CG ( | |||
|---|---|---|---|---|
| Pre | Post | Pre | Post | |
| Anxiety (0–21) | 12.3 ± 5.8 | 6.3 ± 3.9 * | 11.1 ± 4.5 | 8.0 ± 4.8 * |
| Depression (0–21) | 5.2 ± 2.1 | 3.0 ± 1.6 | 7.4 ± 4.7 | 4.9 ± 3.8 |
| Insomnia (0–28) | 9.2 ± 6.5 | 3.0 ± 2.0 * | 13.3 ± 6.2 | 10.1 ± 5.3 |
Data are presented as mean ± SD, TG; Training group, CG; Control group. Score categories anxiety and depression: Normal (0–7); signs of mood disorder (8–10); probable presence of mood disorder (11–21). Score categories insomnia: No clinically significant insomnia (0–7); subthreshold insomnia (8–14); clinical insomnia, moderate severity (15–21); clinical insomnia, severe (22–28). * p < 0.05, difference within group pre- to posttest